The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...

Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely removed by surgery, recurrence or metastasis, the ...

Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy. The accelerated approval was ...

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...

What Is It, and Why Does It Matter? Tecelra (afamitresgene autoleucel) is a prescription-based personalized T-cell immune therapy for treating synovial sarcoma, a rare type of cancer affecting soft ...

At 16, Eldiara Doucette felt pain in her right arm that she struggled to describe. “It could have easily been classified with a standard teenage ‘growing pains,’ which is, unfortunately, how a lot of ...

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma - a rare tumor of soft tissues, such as ligaments and muscles - using an ...

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma—a rare tumor of soft tissues, such as ligaments and muscles—using an ...

July is sarcoma awareness month – an important opportunity to spotlight this rare and devastating disease, the importance of ...

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and ...

Researchers have developed a way to attack synovial sarcoma -- a rare tumor of soft tissues, such as ligaments and muscles -- using an investigational drug that triggers cell death. Researchers at ...